StageZero Life Sciences Ltd
14.3.2022 16:27:02 CET | ACCESS Newswire | Press release
This release replaces and corrects the release that was issued earlier this morning
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692951/CORRECTING-AND-REPLACING-StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Redington MD and Group CEO V.S. Hariharan Appointed to GTDC Executive Committee12.5.2026 15:00:00 CEST | Press release
GTDC appointed V.S. Hariharan, Managing Director and Group CEO of the Redington Group, to its Executive Committee (EC) to guide strategy and provide operational oversight. The EC advances the organization's mission to educate, advocate, and influence the tech industry on the evolving role of IT distribution worldwide. Mr. Hariharan leads Redington's $11.8 billion distribution and supply chain business across 40 markets. Redington continues to strengthen its role as a Technology Orchestrator, enabling seamless connections across the ecosystem to Unlock Next opportunities for partners. TAMPA, FL / ACCESS Newswire / May 12, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, named V.S. Hariharan, Managing Director and Group CEO of Redington Limited, to its Executive Committee. The committee provides operational oversight and helps guide GTDC's long-term strategy, advancing the organization's mission to strengthen distributio
Braiin Advances Proposed Acquisition of Home.cc with Valuation and Growth-Capital Components Totaling Approximately A$73 Million to Build AI-Native LivTech Platform for Residential Lifecycle Services, Targeting the $3+ Trillion Global Residential Lifecycle Services Market12.5.2026 14:15:00 CEST | Press release
Proposed acquisition would combine Home's embedded residential distribution, payments infrastructure and household-services platform with Braiin's AI, CXaaS and PropTech ecosystem MELBOURNE, AU AND LONDON, UK / ACCESS Newswire / May 12, 2026 / Braiin Limited (NASDAQ:BRAI) ("Braiin" or the "Company"), a global AI platform company delivering automation and predictive analytics across precision agriculture, customer experience and property technology, today announced that it has entered into a non-binding term sheet to advance its proposed acquisition of Home.cc ("Home"), a Living Technology ("LivTech") platform focused on embedded residential distribution, household service activation, payments and connected living infrastructure. Under the proposed structure, Braiin would acquire a 50.1% majority interest in Cumbria Capital Ltd, the parent company of Home.cc, through a share purchase to be satisfied by the issuance of Braiin equity securities. The non-binding term sheet contemplates a p
Polaris Renewable Energy Announces Approval of SO1 Agreement by FOMB12.5.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 12, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that, on May 8, 2026, the Financial Oversight and Management Board of Puerto Rico ("FOMB") approved the Battery Energy Storage System ("BESS") Standard Offer Agreement ("SO1 Agreement"). The approval of the FOMB completes the three-steps approval process for the SO1 Agreement, following prior regulatory approvals obtained from the Puerto Rico Energy Bureau ("PREB") and the Governing Board of the Puerto Rico Electric Power Authority ("PREPA"). The SO1 Agreement is intended to be executed between PREPA and Polaris Power US, Inc ("PPUS"), a wholly owned subsidiary of Polaris. The SO1 Agreement forms part of the Puerto Rico Accelerated Storage Addition Program ("ASAP"), a strategic initiative aimed at strengthening grid reliability across the island through the deployment of utility-scale BESS co-located with existing generation facilities. Under this
Elixir Technologies Unveils Elixir Muse: The AI Writing Assistant Built for Total Data Privacy12.5.2026 13:00:00 CEST | Press release
Elixir's new writing assistant product delivers AI-powered drafting, revision, translation, validation, tone of voice and sentiment analysis, and compliance analysis - without storing, harvesting or training on user data. OJAI, CA / ACCESS Newswire / May 12, 2026 / Elixir Technologies today introduced Elixir Muse™, a privacy-first AI writing assistant that significantly minimizes the workload involved in drafting, editing, proofreading and translating text. Powered by Elixir Ai, the company's proprietary AI technology, Elixir Muse™ assists both writers and content creators improve the quality, clarity and consistency of their written content through advanced AI features - all while safeguarding the privacy of user data. Elixir Muse™ introduces a fundamentally different approach to AI-assisted document iteration: one where privacy and control are prioritized from the start, rather than being an afterthought. With user-friendly writing features and proven use cases, the product functions
Dubai Health and AGFA HealthCare Mark 20 Years of Collaboration Supporting Dubai's Healthcare System12.5.2026 11:30:00 CEST | Press release
Dubai Health and AGFA HealthCare have marked 20 years of collaboration supporting Dubai's healthcare system, reflecting a shared commitment to advancing integrated, patient-centered care. DUBAI, AE / ACCESS Newswire / May 12, 2026 / Over the past two decades, AGFA HealthCare has supported Dubai's healthcare system - most recently contributing to Dubai Health's integrated academic health system across care, learning, and research through a shared digital foundation. It enables clinicians access to critical information while maintaining data security, operational continuity, and patient confidentiality, and supports large-scale screening services in high-volume settings. The partnership has progressed from digitizing diagnostic imaging into a comprehensive enterprise imaging, analytics, and AI ecosystem that supports multiple clinical specialties, leadership decision-making, and population-scale healthcare services across Dubai Health's expanding network. Atif Al Braiki, Chief Digital an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom